SCHOLAR ROCK HOLDING CORPORATION Financing Cash Flow
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Financing Cash Flow of $276.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $83.12M, a 1183.87% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $193.79M, a 4548.26% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $73.29M, a 78.84% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $144.47M, a 86929.52% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) financing activities for fiscal 2025 was $228.40M, a 35.30% decline from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) financing activities for fiscal 2024 was $353.03M, a 244.17% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) financing activities for fiscal 2023 was $102.57M, a 47.35% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) financing activities for fiscal 2022 was $194.83M, a 333.43% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $83.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $276.90M 10-Q · filed 2026-08-06 | $350.19M derived: sum of 3 quarters · filed 2026-08-06 | $494.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $193.79M 10-Q · filed 2026-05-07 | $267.07M derived: sum of 2 quarters · filed 2026-05-07 | $411.54M derived: sum of 3 quarters · filed 2026-05-07 | $418.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $73.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $217.76M derived: sum of 2 quarters · filed 2026-03-03 | $224.23M derived: sum of 3 quarters · filed 2026-08-06 | $228.40M 10-K · filed 2026-03-03 |
| 2025-09-30 | $144.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $150.94M derived: sum of 2 quarters · filed 2026-08-06 | $155.11M 10-Q · filed 2025-11-14 | $501.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.64M 10-Q · filed 2026-08-06 | $357.01M derived: sum of 3 quarters · filed 2026-08-06 | $357.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.17M 10-Q · filed 2026-05-07 | $350.54M derived: sum of 2 quarters · filed 2026-05-07 | $350.70M derived: sum of 3 quarters · filed 2026-05-07 | $350.67M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $346.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $346.54M derived: sum of 2 quarters · filed 2026-03-03 | $346.50M derived: sum of 3 quarters · filed 2026-03-03 | $353.03M 10-K · filed 2026-03-03 |
| 2024-09-30 | $166.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $133.00K derived: sum of 2 quarters · filed 2025-11-14 | $6.66M 10-Q · filed 2025-11-14 | $103.19M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $6.49M 10-Q · filed 2025-08-06 | $103.02M derived: sum of 3 quarters · filed 2025-08-06 | $103.30M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $6.53M 10-Q · filed 2025-05-14 | $103.05M derived: sum of 2 quarters · filed 2025-05-14 | $103.33M derived: sum of 3 quarters · filed 2025-05-14 | $108.02M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $96.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $96.81M derived: sum of 2 quarters · filed 2025-02-27 | $101.50M derived: sum of 3 quarters · filed 2025-02-27 | $102.57M 10-K · filed 2025-02-27 |
| 2023-09-30 | $280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.97M derived: sum of 2 quarters · filed 2024-11-12 | $6.04M 10-Q · filed 2024-11-12 | $5.08M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $4.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.76M 10-Q · filed 2024-08-08 | $4.79M derived: sum of 3 quarters · filed 2024-08-08 | $4.34M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.08M 10-Q · filed 2024-05-07 | $106.00K derived: sum of 2 quarters · filed 2024-05-07 | -$345.00K derived: sum of 3 quarters · filed 2024-05-07 | $195.43M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$970.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$1.42M derived: sum of 2 quarters · filed 2024-03-19 | $194.35M derived: sum of 3 quarters · filed 2024-03-19 | $194.83M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $195.32M derived: sum of 2 quarters · filed 2023-11-07 | $195.80M 10-Q · filed 2023-11-07 | $235.50M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $195.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $196.25M 10-Q · filed 2023-08-09 | $235.95M derived: sum of 3 quarters · filed 2023-08-09 | $237.86M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $481.00K 10-Q · filed 2023-05-09 | $40.18M derived: sum of 2 quarters · filed 2023-05-09 | $42.09M derived: sum of 3 quarters · filed 2023-05-09 | $42.70M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $39.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $41.61M derived: sum of 2 quarters · filed 2023-03-07 | $42.21M derived: sum of 3 quarters · filed 2023-03-07 | $44.95M 10-K · filed 2023-03-07 |
| 2021-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.51M derived: sum of 2 quarters · filed 2022-11-14 | $5.25M 10-Q · filed 2022-11-14 | $251.71M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $607.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.34M 10-Q · filed 2022-08-08 | $249.80M derived: sum of 3 quarters · filed 2022-08-08 | $250.17M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $2.74M 10-Q · filed 2022-05-16 | $249.19M derived: sum of 2 quarters · filed 2022-05-16 | $249.56M derived: sum of 3 quarters · filed 2022-05-16 | $250.16M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $246.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $246.82M derived: sum of 2 quarters · filed 2022-03-07 | $247.42M derived: sum of 3 quarters · filed 2022-03-07 | $247.82M 10-K · filed 2022-03-07 |
| 2020-09-30 | $368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $963.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.36M 10-Q · filed 2021-11-09 | $2.18M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $595.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $994.00K 10-Q · filed 2021-08-10 | $1.81M derived: sum of 3 quarters · filed 2021-08-10 | $7.94M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $399.00K 10-Q · filed 2021-05-13 | $1.22M derived: sum of 2 quarters · filed 2021-05-13 | $7.34M derived: sum of 3 quarters · filed 2021-05-13 | $49.44M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $818.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $6.94M derived: sum of 2 quarters · filed 2021-03-09 | $49.04M derived: sum of 3 quarters · filed 2021-03-09 | $48.88M 10-K · filed 2021-03-09 |
| 2019-09-30 | $6.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $48.22M derived: sum of 2 quarters · filed 2020-11-09 | $48.06M 10-Q · filed 2020-11-09 | $64.99M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $42.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $41.94M 10-Q · filed 2020-08-07 | $58.87M derived: sum of 3 quarters · filed 2020-08-07 | $57.41M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$157.00K 10-Q · filed 2020-05-07 | $16.77M derived: sum of 2 quarters · filed 2020-05-07 | $15.31M derived: sum of 3 quarters · filed 2020-05-07 | $94.28M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $16.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $15.46M derived: sum of 2 quarters · filed 2020-03-12 | $94.44M derived: sum of 3 quarters · filed 2020-03-12 | $94.27M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $77.51M derived: sum of 2 quarters · filed 2019-11-12 | $77.34M 10-Q · filed 2019-11-12 | $124.06M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $78.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $78.80M 10-Q · filed 2019-08-14 | $125.52M derived: sum of 3 quarters · filed 2019-08-14 | $125.35M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$167.00K 10-Q · filed 2019-05-15 | $46.55M derived: sum of 2 quarters · filed 2019-05-15 | $46.38M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2017-12-31 | $46.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $46.55M derived: sum of 2 quarters · filed 2019-03-19 | $50.50M 10-K · filed 2019-03-19 | |
| 2017-09-30 | -$167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $3.79M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $3.95M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |